Does WV Medicaid Cover Weight Loss Drugs? GLP-1s and Exceptions

West Virginia Medicaid does not cover prescription drugs used for weight loss. The state’s Bureau for Medical Services excludes anti-obesity medications from its Medicaid formulary, and that policy remains in place as of 2026. Only 13 state Medicaid programs nationwide cover GLP-1 drugs like Wegovy or Zepbound for obesity, and West Virginia is not one of them.¹

The same drug can still be covered when it’s prescribed for a different diagnosis. That distinction is where most denials and most confusion sit, so it’s worth walking through carefully.

Where the Exclusion Comes From

Federal law generally requires state Medicaid programs to cover all FDA-approved drugs from participating manufacturers. But 42 U.S.C. § 1396r-8 carves out a specific exception for “agents used for weight loss,” letting each state decide whether to pay for anti-obesity medications.¹ Most states have used that discretion to say no, and West Virginia is among them.

The pharmacy benefit in West Virginia Medicaid is carved out of managed care entirely. Neither The Health Plan nor Wellpoint handles retail pharmacy claims; every prescription runs through the fee-for-service system under the Bureau for Medical Services Preferred Drug List.² So there is no alternate managed-care pathway for a weight-loss prescription. If BMS excludes it, it’s excluded.

When GLP-1 Drugs Are Covered Under a Different Diagnosis

Federal rules require Medicaid to cover GLP-1 medications when they’re prescribed for FDA-approved indications other than weight loss. West Virginia Medicaid covers semaglutide (Ozempic) and tirzepatide (Mounjaro) when a physician prescribes them for Type 2 diabetes.¹

Two newer approvals broaden the picture. In late 2024, Zepbound received FDA approval for moderate to severe obstructive sleep apnea, and Wegovy gained an indication for reducing cardiovascular risk in patients with obesity. Coverage for those specific indications is mandatory even in states that exclude the drugs when prescribed only for weight management. That’s the piece worth taking to a prescriber: if you have a qualifying comorbid condition, the same molecule may be covered under a different code.

Non-preferred drugs on the West Virginia PDL can also be obtained through prior authorization, though the underlying weight-loss exclusion still applies when weight loss is the sole indication.³

Obesity Treatments Medicaid Does Cover

Weight-loss drugs are off the table, but several other obesity-related services are covered.

Annual adult physical examinations and preventive services, which can include obesity screening and counseling.
Medical nutrition therapy and nutritional consultation.
Bariatric surgery, including gastric bypass, gastric banding, and sleeve gastrectomy, with prior authorization. Eligibility requires a BMI above 40 (or above 35 with a severe comorbidity, or being at least 100 pounds overweight), a history of obesity for at least five years, completion of a 12-month physician-supervised nutrition and exercise program within the prior two years, and a psychological evaluation.⁴
Weight management services, including group exercise classes with nutritional counseling, for members enrolled in the WV Health Home Program or the Mountain Health Choices Enhanced Plan who are pre-diabetic or have obesity-related comorbid conditions.⁴

Outside those specific programs, the state generally does not cover standalone weight-loss programs.

Why Coverage Hasn’t Expanded

West Virginia has tried the drugs on a smaller population and pulled back. The Public Employees Insurance Agency, which covers state workers rather than Medicaid enrollees, ran a pilot that enrolled roughly 1,000 employees and paid for Ozempic, Wegovy, Zepbound, and Mounjaro alongside nutrition and exercise support.⁵ PEIA paused it on March 15, 2024, honoring existing pre-authorizations through June 30, 2024.⁶

Cost was the reason. The pilot ran about $1.3 million per month after manufacturer rebates, and expanding to the intended 10,000 participants was projected at $150 million annually.⁵ Senator Tom Takubo, who chairs the Joint Standing Committee on Insurance and PEIA, said overall GLP-1 spending had reached roughly $90 million and was breaking the agency’s budget.⁶

Legislative attempts to open Medicaid or PEIA to weight-loss drug coverage have not passed:

Senate Bill 743 in the 2024 regular session would have created a supervised Medicaid weight-loss program for members with a BMI of at least 35 and one comorbidity. The Department of Human Services estimated an annual cost of $75.6 million. The bill did not advance.⁷
House Bill 4979 in 2024, which would have mandated insurance coverage of GLP-1 medications, died in the House Committee on Banking and Insurance.⁶
House Bill 116 in the 2024 special session, which would have required PEIA to reimburse members for GLP-1 medications prescribed for weight loss, did not advance out of the House Finance Committee.⁶

The 2026 session’s Make West Virginia Healthy Act (House Bill 4982) focused on nutrition, including a “Food is Medicine” program with medically tailored meals and produce prescriptions. It did not address weight-loss drug coverage.⁸

What Could Change at the Federal Level

A Biden-era proposal that would have reinterpreted the Social Security Act to allow Medicare Part D coverage of anti-obesity drugs was dropped from the final 2026 CMS rule in April 2025.⁹ The Trump administration then rescinded a separate proposal that would have required state Medicaid programs to cover these drugs.¹⁰

In December 2025, CMS launched the BALANCE model, a voluntary five-year initiative designed to negotiate lower GLP-1 prices with manufacturers and offer standardized coverage criteria to participating state Medicaid programs and Medicare Part D plans. States were asked to signal participation by January 8, 2026, with the model expected to begin in May 2026.¹ Whether West Virginia will opt in has not been publicly announced.

Senator Takubo has said lawmakers continue to work behind the scenes with drug manufacturers on a sustainable approach, including developing qualification criteria for any future program.⁶ Until something changes at either the federal or state level, West Virginia Medicaid enrollees seeking a GLP-1 for weight loss alone have no coverage pathway through the state program. The practical next step for most people is a conversation with their prescriber about whether a covered indication applies, or about the surgical and counseling benefits Medicaid does pay for.

1
KFF. Medicaid Coverage of and Spending on GLP-1s
2
Wellpoint. West Virginia Pharmacy
3
WV Bureau for Medical Services. Preferred Drug List and Coverage Details
4
GWU STOP Obesity Alliance. Medicaid Obesity Coverage – West Virginia
5
Senator Shelley Moore Capito. West Virginia Leaders Embrace Effects of Weight Loss Drugs While Also Considering Cost
6
West Virginia Public Broadcasting. State Employee Health Insurance Ends Pilot Program to Treat Obesity-Related Illness
7
West Virginia Watch. West Virginians Say Medications Have Helped Them Lose Weight, but Coverage Can Be a Problem
8
WV Legislature. House Bill 4982 – Make West Virginia Healthy Act of 2026
9
Healio. CMS Decision to Remove Obesity Drug Coverage From 2026 Final Rule Disappoints Societies
10
Stateline. States Retreat From Covering Drugs for Weight Loss